Dr. Wierda on Ibrutinib Plus Venetoclax in CLL

William G. Wierda, MD, PhD
Published: Tuesday, Feb 21, 2017



William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses a clinical trial exploring the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL).

In the clinical trial that is being conducted out of The University of Texas MD Anderson Cancer Center, patients are treated with ibrutinib for 3 months, followed by up to 2 years of the combination with venetoclax (NCT02756897). Wierda, who says he is very excited about the study, says that early findings suggest the combination has activity.

While ibrutinib can shrink lymph nodes, the agent is not as effective at clearing blood or bone marrow of disease. In contrast, venetoclax is effective at these 2 tasks. Clinically, they are complimentary agents.


William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses a clinical trial exploring the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL).

In the clinical trial that is being conducted out of The University of Texas MD Anderson Cancer Center, patients are treated with ibrutinib for 3 months, followed by up to 2 years of the combination with venetoclax (NCT02756897). Wierda, who says he is very excited about the study, says that early findings suggest the combination has activity.

While ibrutinib can shrink lymph nodes, the agent is not as effective at clearing blood or bone marrow of disease. In contrast, venetoclax is effective at these 2 tasks. Clinically, they are complimentary agents.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x